The Brightiva Network was built to help licensed prescribers incorporate a next-generation ketamine formulation into their practice without administrative burden on staff. It was designed to be affordable for patients, expanding access to this treatment without the cost barriers common to other options. Prescribers are supported by a proprietary treatment protocol, clinical guides, optional clinical documentation templates, and a direct pharmacy fulfillment system.
Brightiva is a proprietary dissolvable troche combining three compounds — ketamine, dextromethorphan, and fluoxetine — each selected for a precise pharmacological role. Based on Dr. Hebig’s clinical experience treating thousands of patients over six years, this combination has produced more complete and sustained therapeutic outcomes than ketamine alone.
For patients with specific contraindications to dextromethorphan or fluoxetine, an alternative ketamine-only formulation is available through the Network. No patient needs to be excluded from treatment due to a component contraindication.
The Brightiva treatment protocol was developed and refined by Dr. Hebig over six years of direct patient care. It provides a structured framework for patient selection, dosing, administration, observation, and maintenance.
The complete protocol, dosing guidelines for all four Brightiva formulations, clinical pearls, and documentation templates are available inside the physician portal upon approval.
From application to reorder, Brightiva is built to fit within your practice, not add to its burden.
Complete the registration with your professional details and credentials. Applications are reviewed by the Brightiva team. Upon approval, login credentials are issued by email and portal access is granted immediately. Verification of each prescriber by our ePrescribe partner can take up to 48 hours. Once verified, you can then place orders that will be shipped directly to your clinic door within 2 business days.
Access the physician portal to place orders for individual patients. Bulk ordering is not permitted. Each order is fulfilled by a certified compounding pharmacy partner and shipped directly to your clinic, signature required upon delivery.
Patients self-administer Brightiva under direct clinical observation in an outpatient office setting, as recommended via the proprietary treatment protocol.
Membership requires a non-refundable enrollment fee of $169 at the time of registration. This fee covers the cost of ID verification and ePrescribe integration for controlled medication prescribing. The monthly membership fee is waived provided a minimum of one patient order is placed per calendar month. In any month where no order is placed, $49 will be charged to the credit card on file to maintain active membership and prescribing access. Membership may be cancelled at any time without a cancellation fee, though $49 will be charged for any partial calendar month without an order prior to the cancellation request. Prescribers who cancel and later wish to rejoin will be required to pay the $169 enrollment fee again, regardless of when they cancelled. An active credit card must be kept on file at all times. Brightiva LLC reserves the right to limit or revoke membership access when necessary. Fee structure is subject to change based on market conditions.
Membership is open to psychiatrists, psychiatric NPs and PAs, and any other licensed prescriber with an active DEA registration.
Brightiva ships to all U.S. states except Illinois, Mississippi, Hawaii, and Washington D.C. Prescribers licensed exclusively in these locations are not eligible for network membership at this time.
Applications are reviewed by the Brightiva team. You will receive login credentials by email upon approval. Usually within 1 - 2 business days.
The portal contains the full treatment protocol, dosing guidelines for all Brightiva formulations, clinical documentation templates, supporting research with links to published studies on PubMed, and the secure ordering system.
Brightiva is a compounded medication prescribed off-label by licensed providers. It does not carry an FDA indication for any psychiatric conditions and it is not “FDA approved”. The clinical basis for its components is supported by published research, available in full inside the portal.
You will find the cost in the paid membership section and find that Brightiva is extremely affordable.
No. Your clinic will purchase the protocol and medication and charge the patient accordingly at the time of treatment.
An alternative ketamine-only formulation is available through The Brightiva Network for patients who cannot receive the full Brightiva formula due to a contraindication to dextromethorphan or fluoxetine.
Brightiva contains ketamine, a Schedule III controlled substance under the DEA. Network members are responsible for compliance with all applicable federal and state controlled substance regulations.
Clinical and technical support is available through the Brightiva team Monday through Friday, 9 AM to 5 PM Eastern at admin@brightiva.com.